[Prophylaxis of anemia of prematurity with erythropoietin. Case control study].
To evaluate the effectiveness of recombinant human erythropoietin (rH-EPO) in the prophylactic treatment of anemia of prematurity. We performed a non-randomised, retrospective case control study of 108 premature babies with birth weights of less than 1500 grams and gestational age of less than 34 weeks. Infants with hemolytic or hemorrhagic disease and those who died in the first days of life were excluded. Fifty-four patients were treated with rH-EPO (250 U/kg subcutaneously, 3 times a week) for 6 weeks. A ferrous sulfate supplement was also administered orally (4-6 mg/kg/day) with a multivitamin complex. There were no differences between groups in gestational age, birth weight, ferritin levels, hematocrit and hemoglobin on admission, amount of blood sampled and days with ventilatory support. The number of transfusions per patient were 1.46 +/- 1.38 in control group versus 0.69 +/- 1.19 in rH-EPO-treated infants (p < 0.002). Sixty-three percent of infants in the treated group did not require blood transfusions compared with only 29.7% in the nontreated group (p < 0.001). The lowest mean hemoglobin was 8.72 +/- 2.62 gr/dl in the control group versus 9.70 +/- 2.08 gr/dl in the rH-EPO group. Prophylactic treatment with rH-EPO was effective in reducing the number of transfusions, mainly in stable newborn infants with a birth weight greater than 1000 grams.